On March 21, 2025, Pfizer Inc. disposed of its entire stake in Haleon plc, selling 661,709,764 shares—including 617,553,920 through a secondary offering and 44,155,844 in an off-market sale. This event reflects Pfizer's exit from its residual interest in Haleon.